OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Separately, Maxim Group began coverage on OS Therapies in a research report on Tuesday, November 26th. They set a “buy” rating and a $8.00 price target for the company.

OS Therapies Trading Down 9.6 %

Shares of OSTX stock opened at $3.94 on Wednesday. The company has a 50 day moving average of $3.29. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.